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Abstract
Background: Anti-malarial drug resistance threatens to undermine efforts to eliminate this deadly disease. The
resulting omnipresent requirement for drugs with novel modes of action prompted a national consortium initiative
to discover new anti-plasmodial agents from South African medicinal plants. One of the plants selected for
investigation was Dicoma anomala subsp. gerrardii, based on its ethnomedicinal profile.
Methods: Standard phytochemical analysis techniques, including solvent-solvent extraction, thin-layer- and column
chromatography, were used to isolate the main active constituent of Dicoma anomala subsp. gerrardii. The
crystallized pure compound was identified using nuclear magnetic resonance spectroscopy, mass spectrometry and
X-ray crystallography. The compound was tested in vitro on Plasmodium falciparum cultures using the parasite
lactate dehydrogenase (pLDH) assay and was found to have anti-malarial activity. To determine the functional
groups responsible for the activity, a small collection of synthetic analogues was generated - the aim being to vary
features proposed as likely to be related to the anti-malarial activity and to quantify the effect of the modifications
in vitro using the pLDH assay. The effects of the pure compound on the P. falciparum transcriptome were
subsequently investigated by treating ring-stage parasites (alongside untreated controls), followed by
oligonucleotide microarray- and data analysis.
Results: The main active constituent was identified as dehydrobrachylaenolide, a eudesmanolide-type
sesquiterpene lactone. The compound demonstrated an in vitro IC50 of 1.865 μM against a chloroquine-sensitive
strain (D10) of P. falciparum. Synthetic analogues of the compound confirmed an absolute requirement that the a-
methylene lactone be present in the eudesmanolide before significant anti-malarial activity was observed. This
feature is absent in the artemisinins and suggests a different mode of action. Microarray data analysis identified
572 unique genes that were differentially expressed as a result of the treatment and gene ontology analysis
identified various biological processes and molecular functions that were significantly affected. Comparison of the
dehydrobrachylaenolide treatment transcriptional dataset with a published artesunate (also a sesquiterpene
lactone) dataset revealed little overlap. These results strengthen the notion that the isolated compound and the
artemisinins have differentiated modes of action.
Conclusions: The novel mode of action of dehydrobrachylaenolide, detected during these studies, will play an
ongoing role in advancing anti-plasmodial drug discovery efforts.
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The most critical problem facing malaria treatment today
is resistance to anti-plasmodial drugs. The emerging resis-
tance of Plasmodium falciparum to the only affordable
anti-malarials, chloroquine and sulphadoxine/pyrimetha-
mine, and now even the last effective class of antimalarials,
the artemisinins [1,2], undermines efforts to eliminate or
even manage effectively this deadly disease. Hence, there is
continued interest in the discovery of bioactive natural
compounds with unique structures that may lead to anti-
malarial drugs with novel modes of action [3-5].
South Africa boasts a rich biodiversity with more than
22,600 indigenous plants, representing about 9% of all
higher plants on Earth [6]. There is also a long history of
the use of plants in African traditional healthcare sys-
tems. This natural resource and indigenous knowledge,
together with the historical success of the plant-derived
anti-malarials (i.e. quinine, artemisinin) and the universal
need for new drugs, prompted a national consortium
initiative to discover novel anti-plasmodial agents from
South African plants [7].
One of the plants selected for this study was Dicoma
anomala, an erect, suberect or prostrate herb bearing aro-
matic semi-woody tubers at the base of a woody subterra-
nean stem. This grassland species is widely distributed in
sub-Saharan Africa, and is morphologically diverse, result-
ing in the recognition of several infraspecific taxa. Two
subspecies occur in South Africa: D. anomala subsp.
anomala and D. anomala subsp. gerrardii [4].
The numerous ethnomedicinal uses of D. anomala,
which range from the treatment of coughs and colds,
fevers, ulcers, dermatosis, venereal diseases, labour pains,
dysentery, intestinal parasites, stomach pains, toothache
and internal worms, can be linked to several pharmacolo-
gical properties: anti-bacterial, anti-helmintic, anti-viral,
anti-plasmodial, anti-spasmodic, wound healing, analgesic
and anti-inflammatory [8-11]. A previous study reported
the anti-bacterial and anti-inflammatory properties of the
root extracts of D. anomala [9]. Another study demon-
strated in vitro anti-cancer activity of extracts of a related
species, Dicoma capensis [12,13].
Phytochemical investigations of D. anomala have iden-
tified several classes of secondary metabolites; including
acetylenic compounds, phenolic acids, flavonoids, sesqui-
terpene lactones, triterpenes and phytosterols [14-16].
The investigation of a dichloromethane extract of the
roots of D. anomala resulted in the isolation of asymme-
trical sesquiterpene dimers with potent anti-plasmodial
properties [17,18]. Based on this finding and the reported
use of D. anomala in the treatment of fevers, a primary
symptom of malaria [8,9], an ethyl acetate (EtOAc)
extract of the roots of D. anomala subsp. gerrardii
was assayed against a chloroquine-sensitive strain of
P. falciparum. Its activity warranted further investigation
and a sesquiterpene lactone, dehydrobrachylaenolide
(Figure 1), was isolated by column chromatography and
found to show in vitro activity [11]. Structure-activity
relationship experiments (through the generation and
assessment of simple synthetic analogues) confirmed the
requirement for activity as the a-methylene lactone moi-
ety, a feature absent in artemisinin anti-malarials (artesu-
nate, Figure 2). The compound was further investigated
through transcriptome analysis and comparisons were
drawn between the isolated compound and a related
sesquiterpene lactone, artesunate (Figure 2). Comparative
analysis revealed little overlap and confirmed likely differ-
ent modes of action.
Methods
Plant collection and extraction
Collection of rootstocks of D. anomala subsp. gerrardii
was undertaken in the Brits region of the North West Pro-
vince of South Africa during February 2008. A voucher
(BP 01455) was deposited at the National Herbarium of
South Africa (Pretoria), and the identity of this taxon con-
firmed by Dr E. Retief.
A total of 5.6 kg of fresh rootstock was oven dried
(30°C) and ground with a hammer mill to yield 3.7 kg
of finely processed plant material. Of this, 3.4 kg of the
processed material was consecutively extracted with 3
volumes of EtOAc (15 L) at room temperature over 3
days. The filtered extract was concentrated under
reduced pressure on a rotary evaporator at 60°C and
further dried in a vacuum desiccator for 96 h to remove
all traces of solvent. The extraction yielded 48 g of
brown gum (1.3% w/w of dry plant material).
Isolation and identification of dehydrobrachylaenolide
Solvent partitioning of the crude extract was used to
divide the extract into three fractions with different
ɲͲmethylene
lactone
A B
ɲͲmethylene
ketone
Figure 1 Chemical structure of the sesquiterpene lactone
dehydrobrachylaenolide. The potential conjugate acceptor sites
(circled in blue) and terminology used in the text of this work are
indicated.
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aqueous methanol (MeOH/H2O9 : 1 ,v / v )a n de x t r a c t e d
with hexane (3 × 100 mL). MeOH was removed from
the aqueous methanolic layer under vacuum on a rotary
evaporator; the remaining solution was diluted to
100 mL with H2O and extracted with dichloromethane
( D C M )( 3×1 0 0m L ) .T h eD C Ml a y e r sw e r ec o m b i n e d
and dried over anhydrous Na2SO4, filtered and concen-
trated under vacuum on a rotary evaporator to give a
DCM-soluble fraction. This process was scaled up for
the remaining crude extract.
Large-scale purification of the DCM-soluble fraction
was performed by liquid chromatography in batches of 5
- 10 g of extract on 400 - 500 g of silica gel 60 (0.063 -
0.2 mm) under reduced pressure, using EtOAc/hexane/
DCM/MeOH and acetone/DCM/MeOH gradients.
Pooled fractions were combined on the basis of similarity
of chemical profile as determined by thin-layer chroma-
tography (TLC). Crude fractions 1A-1L were concen-
trated under vacuum on the rotary evaporator. Fractions
1D-1H were combined (3.5 g) on the basis of similarity
of their TLC profile and subjected to further column
chromatography using a 90 cm column packed with silica
gel and eluted with an EtOAc/hexane/DCM/MeOH iso-
cratic solvent mixture (9:45:45:1, v/v) to give fractions
2A-2N. The fractions were combined on the basis of
similarity of the chemical composition determined by
TLC analysis. Further fractionation of 2F (0.4 g) was
achieved by means of flash chromatography, using a 40
cm flash column, packed with flash silica gel (silica gel
60) and eluted with a hexane/DCM/EtOAc/MeOH iso-
cratic solvent mixture (45:45:9:1, v/v). This yielded com-
pound 1, which was recrystallized from 2-propanol to
yield 400 mg (0.013% w/w of dry plant material) of white
orthorhombic crystals.
Compound 1 was identified using standard one- and
two-dimensional nuclear magnetic resonance spectro-
scopic (NMR) experiments; electrospray-ionization mass
spectrometry (ESI-MS); X-ray crystallography and by
direct comparison with published spectral data [19-21].
NMR analysis was carried out on a Varian 400 MHz
Unity spectrometer. The mass spectral data were
obtained from a hyphenated HPLC-UV/MS instrument
(HPLC Waters Alliance 2690 system, equipped with a
Waters 996 photodiode array detector and a triple quad-
rupole Quattro LC Micro mass spectrometer). The mass
spectrometer was set to operate in both the ESI
- and ESI
+ m o d e s( 4 9-4 7 8a m u )w i t hag a i no f1 0 ;t h ec o n ev o l -
tage was varied between 20 and 70 eV; the desolvation
temperature was 450°C; and the source block tempera-
ture was set at 120°C. Crystallography experiments were
conducted on an Oxford Diffraction Excalibur-2 CCD
area detector diffractometer, using Mo-Ka X-radiation
and a graphite-crystal monochromator. Optical rotations
were measured in chloroform at room temperature on a
Perkin-Elmer 241 polarimeter at 589 nm (Na D-line)
using a 1 dm cell.
Parasite cultures
Asexual P. falciparum chloroquine-sensitive 3D7 and D10
cultures, as well as chloroquine-resistant K1 strain cul-
tures, were maintained and synchronized according to
established methods [22,23] in an atmosphere consisting
of 5% oxygen, 5% carbon dioxide and 90% nitrogen. The
parasites were maintained at a 5% haematocrit in RPMI
1640 medium supplemented with 25 mM HEPES, 22 mM
glucose, 0.0088% hypoxanthine, 40 ug/mL gentamycin (all
Sigma) and 0.5% Albumax (Invitrogen).
In vitro anti-malarial assay
The anti-plasmodial activities of the extracts and pure
compounds were determined against the chloroquine-
sensitive D10 and the chloroquine-resistant K1 strains
via the parasite lactate dehydrogenase (pLDH) assay [24].
All test substances were stored at -20°C prior to testing.
Stock solutions of test substances were prepared in 10%
MeOH or 10% DMSO (in water), depending on the solu-
bility, and diluted in Millipore water to prepare 2 mg/mL
solutions, which were stored at -20°C. Chloroquine
diphosphate (Sigma) was used as a reference drug in all
experiments. The test substances were evaluated as ten
serial two-fold dilutions (0.2 - 100 μg/mL final concen-
tration) in medium (two replicates per concentration
point) in duplicate wells. The highest concentration of
organic solvent that the parasites were exposed to was
0.5%, which was shown to have no measurable effect on
parasite viability [7]. Test solutions were mixed with sus-
pensions of infected human red blood cells to achieve a
final haematocrit of 1% and parasitaemia of 2% and incu-
bated for 48 h in microtitre plates (250 uL final volume).
Incubation conditions were as described above for the
routine maintenance of the P. falciparum cultures. The
Figure 2 Chemical structure of the sesquiterpene lactone
artesunate.
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activities, were calculated by non-linear regression dose-
response analysis using GraphPad Prism v.4.0 software.
In vitro cytotoxicity assay
Compounds were tested for in vitro cytotoxicity against a
Chinese hamster ovary (CHO) cell line using the MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] assay [25]. The CHO cells were cultured in
DMEM: Hams F-12 medium (1:1) supplemented with
10% heat-inactivated foetal calf serum (FCS) and genta-
mycin (0.04 μg/mL) (Highveld Biological, RSA). Samples
were dissolved in 10% MeOH. Stock solutions (2 mg/mL)
were prepared and were stored at -20°C until use. The
samples were added to CHO cells as five ten-fold serial
dilutions ranging from 100 - 0.01 μg/mL. A serial dilution
of emetine (100 - 0.001 μg/mL) was used as a positive
control. Cells were seeded in 96-well plates at a concen-
tration of 10
5/mL (100 μL per well) and incubated at
37°C for 24 h in a humidified 5% CO2-air atmosphere.
The medium was subsequently aspirated from the wells
and replaced with 200 μL of the test compound dilutions.
The microplates were incubated at 37°C for 48 h, after
which 25 μL of sterile MTT (5 mg/mL in PBS) was
added to each well and incubation was continued for 4 h
at 37°C. Formazan crystals formed by viable cells were
dissolved in DMSO and quantitated by measuring absor-
bance at 540 nm in a microtitre plate reader (Cambridge
Technologies). Cell viabilities were calculated relative to
reference wells containing no test compounds (positive
cell controls) and no cells (background controls), plotted
against log[test sample] and IC50 values derived by non-
linear regression analysis using GraphPad Prism v.4.0
software.
Generation of synthetic analogues of compound 1
Information on the synthesis of compound 1 analogues
for structure-activity relationship studies is provided
[see Additional file 1].
Transcriptome analysis
Parasite drug treatment and RNA extraction
P. falciparum 3D7 cultures were treated with 12.5 μMo f
compound 1, corresponding to an inhibitory concentra-
tion of IC99 as determined from dose-response curves. A
morphological comparison between compound 1 treated
versus untreated parasites was performed to assess the
effect of treatment and to establish sampling times, by
examining the stage-specific progression of parasites
across the intra-erythrocytic development cycle. The sol-
vent (DMSO) or compound 1 was added in the window
shortly after red blood cell (RBC) invasion and parasite
development was monitored 6 hourly over a 48 h period
using conventional Giemsa-stained smears. Fresh
cultures were scaled up to 50 ml (5% hematocrit, 10%
parasitemia), synchronized twice and treated with com-
pound 1 in the window around invasion. Fifteen millili-
ters of culture was harvested at each of the stages used
for transcriptional analyses (2, 6 and 12 hpt). Similar
volumes were harvested from untreated P. falciparum
3D7 control cultures at the same time points. Parallel
drug treatments were conducted, serving as biological
replicates. RNA was extracted from the frozen erythro-
cyte pellets as described [26].
Universal Reference RNA (URR) pool, cDNA synthesis and
hybridization
The URR pool was constructed from mixed-stage cultures
as described [26]. cDNA synthesis and hybridizations was
as described in [26], with the exception that 40 pmoles of
each dye was hybridized to each array, utilising Cy3 (sam-
ple) and Cy5 (reference) dyes from GE Healthcare
(#RPN5661), specifically optimized for nucleic acid
labelling.
Microarray data analysis and real-time quantitative PCR
(RT-qPCR)
Generation of GenePix results (gpr) files, LIMMA and
MARRAY analysis in the R computing environment, cal-
culation of Pearson correlation coefficients and determina-
tion of differentially expressed genes were performed as
detailed in [26]. RT-qPCR was performed on an Applied
Biosystems 7500 Fast cycler (Carlsbad, California, USA)
as described [26]. qPCR primers were designed using Pri-
mer3 Plus [27] and sequences are available on request.
PCR efficiencies for each sample were calculated using
LinRegPCR, software described in [28]. Fluorescence data
per cycle of each sample is exported from the Applied Bio-
systems 7500 Fast cycler, from which the efficiencies of
individual samples were calculated. These efficiencies were
used to calculate relative expression in a mathematical
model described by Pfaffl [29]. Gene ontology analyses
were performed using the Micro Array Data Interface for
Biological Annotation (MADIBA) software [30].
Results
Isolation and identification of compound 1
In the search for novel anti-malarials from South African
plants, an EtOAc extract of D. anomala subsp. gerrardii
was screened against the chloroquine-sensitive D10 strain
of P. falciparum using the pLDH assay. The extract
exhibited an IC50 of 1.4 μg/mL [11].
A phytochemical investigation of this extract resulted in
the isolation of a major compound, compound 1. NMR
analysis revealed the presence of an a-methylene-g-lactone
moiety and two fused cyclohexane rings forming the skele-
ton of the eudesmanolide-type sesquiterpene lactone. The
A ring was found to possess a 1,2-endocyclic double bond,
a carbonyl at C-3 and an additional exocyclic methylene
at C-4. Compound 1 was subsequently identified as
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was identical to the structure of dehydrobrachylaenolide
(Figure 1, see Additional file 2), previously isolated from
Brachylaena transvaalensis [20], Hieracium intybaceum
[31] and various Dicoma species [16], all of the Asteraceae
family. A successful chemical synthesis, which confirmed
the structure and absolute configuration of dehydrobrachy-
laenolide, has been reported [21].
The relative configuration of the asymmetric centres
at C-5, C-6 and C-7 was deduced to be trans based on
the size of the observed
1H NMR coupling constants
and NOE correlations. This was in good agreement with
previously reported configuration data for dehydrobra-
chylaenolide [16,32], and was subsequently confirmed by
X ray crystallography and optical rotation studies [33].
In vitro anti-plasmodial activity of
dehydrobrachylaenolide and its synthetic analogues
The eudesmane-type natural compounds are expected to
have various biological activities due to their chemical
structure [21] but the anti-malarial activity of dehydro-
brachylaenolide has not yet been reported. Sesquiterpene
lactones are known to have anti-plasmodial activities
[34-37] and, therefore, the isolated dehydrobrachylaeno-
lide was tested for potential activity against P. falciparum.
Toxicity against mammalian CHO cells was used to
derive a therapeutic index for the test compound [11].
The results are summarized in Table 1.
The compound had an IC50 of 1.865 μM (0.455 μg/mL)
against the chloroquine-sensitive D10 strain and 4.095 μM
(1.0 μg/mL) against the chloroquine-resistant K1 strain
when tested in vitro [see Additional file 3]. Dehydrobra-
chylaenolide can therefore be considered a hit, because it
complies with the basic criteria for anti-parasitic drug dis-
covery [38] with an in vitro IC50 against whole protozoa of
≤ 1 μg/ml and a selectivity of close to ten-fold more
against the chloroquine-sensitive parasites than against the
CHO cells (see therapeutic index, Table 1).
The working assumption in assessing active functionality
was that the levels of unsaturation in the eudesmanolide,
in particular the a-methylene lactone within dehydrobra-
chylaenolide (Figure 1), would be responsible for the
observed activity. Several analogues (2 - 6) were synthe-
sized to investigate the structure-activity relationships
within dehydrobrachylaenolide and are depicted in
Table 2. Due to the time frames involved in obtaining per-
mits for plant collection, plant collection, and metabolite
isolation, a semi-synthetic analogue (2) of dehydrobrachy-
laenolide (1) was generated by reducing the a-methylene
appended to the ketone in the A-ring and increasing the
unsaturation of this ring. The synthetic analogue (2) gen-
erated lacked the anti-malarial potency of the natural pro-
duct (1), being six-fold less active against the D10 strain.
However, this activity was considered sufficient to examine
functional group relationships to activity. Reduction of the
a-methylene appended to the lactone yielded santonin (3),
which was devoid of any significant anti-malarial activity
or mammalian toxicity (as measured by activity against
CHO) at the upper concentrations of the biological assays.
As expected, complete removal of unsaturation in the
A-ring resulted in the generation of a compound (4) lack-
ing both activity and toxicity. Re-introduction of the exo-
cyclic methylene to the lactone resulted in a singly
unsaturated derivative (5) which displayed moderate anti-
malarial activity (about half the potency of the parent (2)).
The CHO-based toxicity of this species was, however, sub-
stantially reduced (about twenty-fold from the synthetic
parent (2) and almost ten-fold from the natural product).
The re-introduction of limited unsaturation in the A-ring
(6), (tested as a mixture) resulted in no significant
improvement in anti-malarial activity with respect to (5),
but increased mammalian cell toxicity.
Transcriptome analysis of dehydrobrachylaenolide
inhibition
Culturing, drug treatment and RNA extraction
A morphological analysis was performed with dehydro-
brachylaenolide to ascertain the point during intra-ery-
throcytic development at which P. falciparum 3D7
growth was affected. Drug treatments were performed in
the window following RBC invasion (i.e. during the early
ring stage growth phase). No significant morphological
differences were observed between treated and control
cultures immediately following drug administration
Table 1 In vitro activity of dehydrobrachylaenolide against P. falciparum
Compound D10
IC50 (μM)
n=8
K1
IC50 (μM)
n=4
CHO
IC50 (μM)
n=2
D10
TI
K1
TI
Dehydrobrachylaenolide 1.865 ±0.254 4.095 ±0.579 17.199 9.2 4.2
Chloroquine 0.038 0.200 35.800 942 179
D10 = P. falciparum - chloroquine-sensitive strain
K1 = P. falciparum - chloroquine-resistant strain
CHO = Chinese hamster ovary cells
n = number of technical replicates averaged - each independent experiment performed in duplicate
TI = Therapeutic index i.e. CHO IC50/anti-plasmodial IC50
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majority of the treated parasite cultures were already
observed to be developing slower than the untreated cul-
tures (Figure 3). Clear differences in morphological
development were visible at 12 hpt (T = 12), where vir-
tually all treated parasites were smaller in size and abnor-
mal in shape compared to the control cultures. Treated
parasites remained arrested in the ring phase throughout
the rest of the 48-hour intraerythrocytic cycle, by the
end of which they were observed to be disintegrated,
shrivelled or compact. Based on these morphological
observations and the apparent rapid effect of dehydrobra-
chylaenolide on P. falciparum development, sampling
times for transcriptional analysis were subsequently
determined as 2, 6 and 12 hpt. RBC Giemsa-stained
smears taken at these time points confirmed the onset of
Table 2 Analogues generated for determination of active sub-structures
Structure D10 strain IC50
(μM)
n=2
K1 strain
IC50
(μM)
n=2
CHO IC50 (μM)
n=2
1.865* 4.095
# 17.2
11.5 9.05 7.01
> 40 NT > 400
> 40 NT > 400
22.1 NT 124
16.9 NT 41.9
n = number of technical replicates averaged - each independent experiment performed in duplicate with several independent experiments performed for the
parent compound dehydrobrachylaenolide.
*n=8
# n=4
DMSO
control
Ref31
treated
2hpt 6hpt 12hpt
0hpt
UT2
T2
UT6 UT12
T12 T6
0.57
0.82
0.88
0.84 0.84
0.91
DMSO
control
Drug
treated
Figure 3 Morphological analysis of P. falciparum 3D7 following addition of dehydrobrachylaenolide at three time points and Pearson
correlation values between treated and untreated samples.
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this timeframe.
Gene expression profiling of P. falciparum treated with
dehydrobrachylaenolide
A microarray reference design experimental strategy,
similar to that described in [26] was employed to ascer-
tain global gene expression in parasites perturbed with
dehydrobrachylaenolide. Labelled cDNA was hybridized
to Operon oligonucleotide microarrays, interrogating
4585 unique genes. All data has been deposited in the
NCBI’s Gene Expression Omnibus (GEO) database, GEO
number GSE29874. Pearson correlation coefficient values
for both technical and biological variation were calcu-
lated in Microsoft Excel. Technical variation across all
arrays was calculated to be 0.89 ± 0.13; whereas biologi-
cal variation across all slides was calculated as 0.78 ±
0.16. Datasets were collated into untreated (UT2,U T 6
and UT12) and treated (T2,T 6 and T12) samples at each
time point before calculation of Pearson correlation coef-
ficients between drug-treated and control samples. Cor-
relation coefficients suggested that parasites remained in
similar states across the different time points after dehy-
drobrachylaenolide treatment, as can be gauged from
coefficients between T2 and T6 (0.88) and T6 and T12
(0.91). The correlation between T2 and T12 was calcu-
lated as 0.82, indicating a growth delay close to or around
6 hpt. This notion is strengthened by the fact that Pear-
son correlation between UT6 and T12 was 0.70, while the
parallel comparison (UT12 and T12) was calculated at
0.57. For differential gene expression analyses, T2 para-
sites were contrasted to UT2,a n dT 12 and T6 parasites
contrasted to UT6. A full table of correlation values
between all collated samples is provided [see Additional
file 4]. A total of 572 unique genes were differentially
regulated (cumulatively across all time points) at least
two-fold and with a false discovery rate (FDR) cut off of
5% following parasite perturbation with dehydrobrachy-
laenolide (all genes listed in Additional file 5). The num-
ber of differentially regulated genes represents 12.5% of
the genes present on the array. Of these, 297 were upre-
gulated (52% of the total), and 275 downregulated (48%
of the total). The number of differentially expressed tran-
scripts increased with time following drug addition, as
expected from Pearson correlations, which indicates a
drug effect on parasite transcription at approximately 6
hpt. Affected transcripts for T2,T 6 and T12 were 134, 291
and 378, respectively. Several transcripts were differen-
tially expressed at more than one time point (e.g. T2 and
T6 or T6 and T12). Due to the cytocidal nature of sesqui-
terpene lactones [39,40], the high treatment dose (IC99)
and the rapid time of action of dehydrobrachylaenolide,
the transcriptional changes observed at the last time
point (T = 12) were regarded as less informative concern-
ing mode of action and were not analysed further. In a
related transcriptome investigation of P. falciparum para-
sites treated with lethal doses of artesunate (a derivative
of the sesquiterpene lactone artemisinin), time points
were harvested after 90 minutes and 3 hours resulting in
398 differentially affected genes [41].
Differentially expressed transcripts were validated by
analysing their expression by real-time quantitative
PCR (RT-qPCR). The expression of three transcripts
(MAL7P1.93 (mitochondrial ribosomal protein S8, puta-
tive), MAL7P1.175 (hypothetical protein) and PFL0055 c
(protein with DNAJ domain (resa-like), putative)) was eval-
uated by qPCR, utilising PFL0625 c (eukaryotic transla-
tional initiation factor 3) as an endogenous control, as
described previously [26].
There was a good concordance between expression
levels from array analysis and those determined by
qPCR (Table 3). At 2 hpt, the expression values (log2)
for MAL7P1.93 were 1.09 and 1.29 for array and qPCR
analyses respectively, and those for MAL7P1.175 were
1.89 and 2.02. Furthermore, the array expression values
for the endogenous control were unchanged (log2 values
at 2 and 6 hpt were 0.0037 and -0.0946, respectively).
MADIBA analyses for metabolic pathways enriched fol-
lowing drug perturbation indicated that several metabolic
pathways were involved in the parasite’s response to per-
turbation with dehydrobrachylaenolide. At T2, transcripts
involved in 20 metabolic pathways were affected; at T6,
this increased to 26. The only metabolic pathway with an
appreciable p-value (in Fisher’sc o n t i n g e n c yt e s ti n
MADIBA) was “Biosynthesis of type II polyketide back-
bone”,a f f e c t e da tT 6 (p = 0.190). However, there is scant
information regarding this pathway in the parasite.
Higher p-values are expected from these analyses, since
all affected transcripts at a given time point are submitted
for analyses, without clustering, as described [26].
Gene Ontology (GO) analysis for genes affected by
dehydrobrachylaenolide treatment, for both Biological
Process and Molecular Function, were performed using
MADIBA software [30]. Biological Process GO terms
Table 3 Comparison of expression values (log2)* as
determined by transcriptome analysis and RT-qPCR
PlasmoDB ID array RT-qPCR array RT-qPCR
2 hpt 2 hpt 6 hpt 6 hpt
MAL7P1.93 1.09 1.29 1.35 2.12
MAL7P1.175
(oligo 1)
1.89 2.02 1.27 2.11
MAL7P1.175
(oligo 2)
1.98 1.7
PFL0055c 1.5 3.38 2.17 2.61
eTFIII (PFL0625c) 0.0037 housekeeping -0.0946 housekeeping
*Data numerical values were transformed to the log base 2 in order to treat
gene induction and repression on an equal level mathematically.
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rected p < 0.05) included chromatin silencing and
dephosphorylation. Additional Biological Process GO
terms included electron transport and DNA replication
(T2) and tRNA modification (T6). The Molecular Func-
tion GO term chromatin binding appeared at both T2
and T6; as did histone binding. In addition, pepsin A
activity (T2), actin binding and sugar metabolism (T6)
were affected. The GO terms are listed in Table 4.
Discussion
The EtOAc extract of D. anomala subsp. gerrardii
showed sufficient activity against P. falciparum to war-
rant further investigation. Compound 1, dehydrobrachy-
laenolide, isolated as a major component of this extract,
was subsequently screened for its anti-plasmodial activity
and found to exhibit some activity against a chloroquine-
sensitive D10 strain and a chloroquine-resistant K1 strain
of P. falciparum.T h i si st h ef i r s tr e p o r to fa n t i - m a l a r i a l
activity associated with this compound.
Dehydrobrachylaenolide was originally isolated from
the roots of Brachylaena transvaalensis,f r o mw h i c hi t s
name was derived [20]. Several biological activities were
reported for this natural product. These included inhibi-
tory activity toward induction of intracellular adhesion
molecule-1 (ICAM-1) [21] and anti-bacterial properties
[42]. It was also shown to have significant anti-cancer
activity in the NCI’s 60-cell line panel, with a selectivity
trend towards the leukaemia sub-panel [11].
The activity of dehydrobrachylaenolide against the
chloroquine-sensitive strain (IC50 = 1865 nM) is within
an order of magnitude of that of quinine (IC50 =1 9 4
nM) [43]. Furthermore, against the chloroquine-sensitive
strain, the compound has a therapeutic index of 9.2,
which is close to the acceptable value of 10 for potential
development [38].
To establish the chemical moieties responsible for the
inhibition of P. falciparum inhibition by dehydrobrachy-
laenolide, synthetic analogues of dehydrobrachylaenolide
were tested against P. falciparum utilising the pLDH
assay. From these studies, it was concluded that the anti-
malarial activity was mainly attributable to the conjugate
acceptor properties of the methylene lactone and the
methylene ketone (in the A-ring, Figure 1). The natural
product possessed two readily accessible acceptor groups
of this type and the absence or inaccessibility of the
methylene ketone was responsible for a ten-fold enhance-
ment in activity without concomitant increase in toxicity
(or, possibly, a two-fold reduction in toxicity), suggesting
that toxic liabilities were largely associated with the
methylene lactone. Further examinations relating to the
role of A-ring geometry and functionalization could be
warranted.
Previously, the authors successfully applied a func-
tional genomics approach to study the effects on the
P. falciparum transcriptome of treatment with cytostatic
drugs (i.e. DFMO/MDL73811 co-inhibition [44] and
cyclohexylamine [26]). In the study presented here, gene
expression profiling was performed on a parasitic cytoci-
dal compound, dehydrobrachylaenolide, subsequent to
its isolation, identification, demonstrated anti-malarial
activity and structure-activity relationship (SAR) studies.
Gene expression profiling of another sesquiterpene
lactone, artesunate [41], reported 398 genes that were
differentially expressed compared to untreated P. falci-
parum parasites. Further to the SAR analyses, comparison
Table 4 Gene Ontology terms enriched following addition of dehydrobrachylaenolide at 2 and 6 hours post-treatment
(at p < 0.05)
Time post treatment Biological process Molecular function p-value Corrected p-value
(false discovery rate, p < 0.05)
chromatin silencing 0.00056108 0.0026184
dephosphorylation 0.0016571 0.0069599
electron transport 0.018276 0.036552
DNA replication 0.027838 0.048717
2 hpt chromatin binding 0.00076337 0.0049195
histone binding 0.0018045 0.0095146
pepsin A activity 0.019635 0.049515
chromatin silencing 0.0022313 0.0096688
dephosphorylation 0.0064848 0.018577
tRNA modification 0.012566 0.029149
6 hpt chromatin binding 0.00047321 0.0031305
actin binding 0.003905 0.011994
sugar metabolism 0.0082591 0.022196
histone binding 0.0082591 0.022196
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dataset of 340 genes (unique genes differentially expressed
at T2 and T6), resulted in only 7.65% (26 genes of the 340)
overlap. This marked difference underscores their prob-
able different modes of action, particularly since, despite
being a sesquiterpene lactone, deydrobrachylaenolide does
not contain the endoperoxide bridge that is characteristic
of the artemisinins and key to their biological activity [45].
In contrast, the a-methylene-g-lactone moiety, as well as
the conformation of the A-ring (Figure 1) of dehydrobra-
chylaenolide, which is absent in the artemisinins, is signifi-
cant for various biological activities of the eudesmane
sesquiterpene lactones [11,46]. The structure-activity rela-
tionship studies performed for dehydrobrachylaenolide
confirmed this.
Conclusions
In this investigation the active constituent of Dicoma
anomala subsp. gerrardii was isolated and identified as
dehydrobrachylaenolide, an eudesmanolide-type sesqui-
terpene lactone. The compound demonstrated in vitro
anti-malarial activity against a chloroquine-sensitive
strain of P. falciparum. Structure-activity relationship
studies indicated that exocyclic methylene residues on
both the lactone and A-ring appear to be responsible
for the observed anti-malarial activity [11]. This methy-
lene lactone moiety is absent in the artemisinin anti-
malarials, indicating a differentiated mode of action to
the artemisinins. Gene expression profiling via microar-
ray strengthened the notion that dehydrobrachylaenolide
displays a different mode of action compared to artesu-
nate [41].
In light of the development of resistance against stan-
dard anti-malarials (now also including the artemisinins
[1,2]) and the quest for new drugs with novel modes of
action, this finding is significant and underscores the
potential of dehydrobrachylaenolide as a potential drug
lead. Some recent examples of so-called pro-drugs of
sesquiterpene lactones, namely ambrosin, arglabin,
parthenin and parthenolide, demonstrate the value of
sesquiterpene lactones as lead compounds for the devel-
opment of pharmaceuticals [47-52].
It can be concluded that dehydrobrachylaenolide could
play a valuable role as a drug lead. Further mechanistic
studies and an in vivo dose response toxicity study
would be necessary to gain in-depth knowledge of the
structural requirements for selectivity, with respect to
the desired biological activity, and systemic toxicity.
Additional material
Additional file 1: Generation of synthetic analogues. The file contains
a description of the synthesis of dehydrobrachylaenolide analogues for
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Additional file 2: Chemical and physical data (including the NMR
assignments) of compound 1. The file contains the chemical and
physical data (including the NMR assignments) of compound 1 used to
identify it as dehydrobrachylaenolide.
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Additional file 4: Microarray correlation values between samples at
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falciparum following dehydrobrachylaenolide treatment. File
contains lists of differentially up- and downregulated gene identifications
(IDs), annotations and relative expression values at each time point
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